Findings from a biomarker analysis of the phase 3 AtTEnd trial (NCT03603184) showed that high whole-exome sequencing (WES)–aneuploidy scores (W-AS) were associated with poorer outcomes with the addition of atezolizumab (Tecentriq) to…
WES-Aneuploidy Scores May Be Prognostic for Immunotherapy in dMMR Endometrial Cancer
